Clinical experience of using mineral water and vitafonotherapy in the complex treatment of patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease
Izha A. Clinical experience of using mineral water and vitafonotherapy in the complex treatment of patients with chronic viral hepatitis C with concomitant non-alcoholic fatty liver disease. Balneo Research Journal. 2020; 11(2): 230-235. doi: https://doi.org/10.12680/balneo.2020.345
Chronic viral hepatitis C (CHC) remains a significant medical and social problem worldwide and is a leader in the structure of etiological factors in the development of diffuse liver diseases (NAFLD). The presence of NAFLD in patients with chronic hepatitis C accelerates the progression rate of HCV infection and reduces the effectiveness and tolerability of antiviral therapy. The above circumstances initiated us to the search for new non-drug technologies for the treatment of this category of patients. The purpose of these work is evaluate the effectiveness of the integrated use of standard antiviral therapy, the drinking of low-mineralized silicon sodium bicarbonate mineral water (MW), and vibroacoustic therapy (VT) in patients with chronic hepatitis C with concomitant NAFLD. Research methods: anamnestic and clinical, general clinical, biochemical, serological (markers of viral hepatitis C, HCV RNA PCR (qualitative and quantitative determination, genotyping), quantitative determination of total endogenous α-interferon in the blood serum, ultrasonographic studies of the digestive system, statistical methods. Fifty patients with chronic hepatitis C (genotype 1b in the phase of replication, minimal and moderate activity) with concomitant NAFLD were examined. Patients were divided into two groups. Patients of the I (control) group (25 people) received the basic treatment complex, which included dietary nutrition (diet No. 5), standard antiviral therapy (AVT) (interferon alfa-2 b and ribavirin) for 12 months and internal intake of MW for the first month of treatment. Patients of group II (25 people), in addition to the basic complex of treatment, additionally received VT procedures, the course of which was six months. Evaluation of the effectiveness of treatment was carried out after 1, 3, 6, and 12 months from the start of treatment. The treatment in both groups was accompanied by the positive dynamics of most of the signs of the disease; however, a significant advantage of using VT was found. In patients of group II, the side effects of AVT – influenza-like and cytopenic syndromes – disappeared, interferonogenesis was stimulated, which made it possible to complete the AVT course in 92.00% of patients and obtain a virological response in 56.00% of patients. In other cases, reduce the virological load by no less than 2 log.